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Propositions
Belonging to the thesis entitled
Prognostic and predictive biomarkers in oesophagogastric cancer
1. The frequency of tumour based molecular alterations including KRAS 
mutation, KRAS amplification, Epstein-Barr virus and microsatellite 
instability is low in oesophagogastric cancer (this thesis)
2. Treatment de-escalation strategies should be considered for gastric cancer 
patients with a very high number of tumour infiltrating lymphocytes as 
these patients have no survival benefit from adjuvant chemotherapy  
(this thesis).
3. Heterogeneity of the tumour stroma content between biopsy pieces 
predicts benefit from cytotoxic chemotherapy in oesophageal cancer 
patients from the Oe02 trial and may represent a clinically useful 
biomarker for patient treatment stratification (this thesis).
4. Successful translation of biomarkers to the clinic requires completion of 
biomarker development roadmaps agreed by the scientific community 
including prospective analysis of retrospectively collected material from 
phase III clinical trials (this thesis).
5. Clinical application of predictive biomarkers has the potential to reduce 
healthcare costs and at the same time improve survival and quality of life 
for oesophagogastric cancer patients, as only those who benefit from 
chemotherapy would be treated (valorisation, this thesis).
6. Unbiased science requires publication of negative results as well as positive 
results to prevent wasted efforts and facilitate progress in the field.
7. Complex scientific problems are best solved by collaboration with experts 
from a variety of cross-disciplinary areas with different expertise.
8. “It’s far more important to know what person the disease has than what 
disease the person has” – Hippocrates
9. If you never try, you’ll never know
Lindsay C. Hewitt, 28 November 2019
